First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The main aim of the present study is to evaluate the clinical efficacy of first-line
dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic
leukemia. In this study, the investigators will analyze the clinical outcomes for entire
patient population as well as those for transplants, respectively. In addition, the results
of this study will be compared to those of the investigators current study (imatinib plus
conventional chemotherapy). The safety of this treatment will also be studied.